Finerenone Should NOT Be Used in Dialysis Patients
Finerenone is contraindicated in patients on chronic dialysis and should not be prescribed in this population. The KDIGO 2024 guidelines explicitly restrict finerenone use to patients with eGFR >25 mL/min/1.73 m², which excludes all dialysis patients who by definition have kidney failure (eGFR <15 mL/min/1.73 m² or on renal replacement therapy) 1.
Why Dialysis Patients Are Excluded
Guideline-Based Restrictions
The KDIGO 2024 guidelines provide clear eGFR thresholds for finerenone initiation:
- Minimum eGFR requirement: >25 mL/min/1.73 m² 1
- Dosing is stratified as:
- 10 mg daily if eGFR 25-59 mL/min/1.73 m²
- 20 mg daily if eGFR ≥60 mL/min/1.73 m²
- Finerenone should be held when eGFR falls below 25 mL/min/1.73 m²
Dialysis patients have eGFR values effectively at 0-15 mL/min/1.73 m², placing them well below the minimum threshold for safe use.
Evidence Base Excludes Dialysis Patients
All major clinical trials establishing finerenone's efficacy (FIDELIO-DKD, FIGARO-DKD) specifically excluded patients with eGFR <25 mL/min/1.73 m² 2, 3. The FIDELITY pooled analysis, which included 12,990 patients, only enrolled those with eGFR ≥25 mL/min/1.73 m² 2. There is no safety or efficacy data for finerenone in dialysis patients.
Hyperkalemia Risk Is Prohibitive
Dialysis patients already face significant hyperkalemia risk due to:
- Inability to excrete potassium renally
- Intermittent dialysis leaving periods of potassium accumulation
- Common use of RAS inhibitors
Finerenone substantially increases hyperkalemia risk even in patients with preserved kidney function. In clinical trials, hyperkalemia occurred in 13.7-14.3% of finerenone-treated patients versus 5.7-8.3% with placebo 2. In dialysis patients, this risk would be exponentially higher and potentially life-threatening.
Clinical Context
The 2024 BMJ guideline on diabetes therapeutics provides a weak recommendation AGAINST finerenone even in CKD patients with moderate cardiovascular/kidney risk, citing "little or no benefit" and risk of severe hyperkalemia 4. This conservative stance in patients with functioning kidneys makes the case against use in dialysis patients even stronger.
Common Pitfall to Avoid
Do not extrapolate finerenone's benefits in earlier-stage CKD to dialysis patients. The mechanism of action (reducing aldosterone-mediated kidney damage and fibrosis) requires functioning nephrons to be clinically meaningful. In dialysis patients with end-stage kidney disease, there is no residual kidney function to protect.
What About Cardiovascular Benefits?
While finerenone reduces cardiovascular events in CKD patients 3, this benefit has not been demonstrated in dialysis populations. The cardiovascular composite outcome reduction (HR 0.88) was shown only in patients with eGFR ≥25 mL/min/1.73 m² 3. Without safety data and with prohibitive hyperkalemia risk, pursuing theoretical cardiovascular benefits in dialysis patients is not justified.
Alternative Approaches for Dialysis Patients
For cardiovascular and residual kidney protection in dialysis patients, consider:
- Optimized dialysis adequacy and volume management
- Careful blood pressure control with dialyzable antihypertensives
- SGLT2 inhibitors may be considered in patients with residual urine output (though evidence is limited)
- Standard heart failure therapies if indicated (beta-blockers, etc.)
Bottom line: Finerenone has no role in the management of dialysis patients and should not be prescribed in this population due to lack of evidence, absence of therapeutic target (functioning nephrons), and unacceptable hyperkalemia risk 1.